baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Knock-Out REGN/ DE000JA9BUA5 /

24/01/2025 18:54:44	Chg.-0.03	Bid22:00:34	Ask22:00:34	Underlying	Strike price	Expiration date	Option type
1.76EUR	-1.68%	- Bid Size: -	- Ask Size: -	Regeneron Pharmaceut...	501.9545 -	31/12/2078	Call

GlobeNewswire 26/08/2024 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...

GlobeNewswire 26/08/2024 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...

GlobeNewswire 21/08/2024 Regeneron Provides Update on Biologics License Application for Linvoseltamab

GlobeNewswire 07/08/2024 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast

GlobeNewswire 01/08/2024 Regeneron Reports Second Quarter 2024 Financial and Operating Results

GlobeNewswire 31/07/2024 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation

GlobeNewswire 03/07/2024 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...

GlobeNewswire 28/06/2024 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...

GlobeNewswire 27/06/2024 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...

GlobeNewswire 26/06/2024 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 16/06/2024 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...

GlobeNewswire 11/06/2024 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...

GlobeNewswire 31/05/2024 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 31/05/2024 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 23/05/2024 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...

GlobeNewswire 20/05/2024 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 17/05/2024 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...

GlobeNewswire 13/05/2024 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...

GlobeNewswire 08/05/2024 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...

GlobeNewswire 06/05/2024 Regeneron Announces Investor Conference Presentations

GlobeNewswire 02/05/2024 Regeneron Reports First Quarter 2024 Financial and Operating Results

GlobeNewswire 29/04/2024 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...

GlobeNewswire 25/04/2024 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...

GlobeNewswire 24/04/2024 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...

GlobeNewswire 22/04/2024 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...

JP Morgan Knock-Out REGN/ DE000JA9BUA5 /

If you wish to receive reply to your feedback, please provide your email address.